These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32213382)

  • 1. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
    Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers.
    Vaclova T; Grazini U; Ward L; O'Neill D; Markovets A; Huang X; Chmielecki J; Hartmaier R; Thress KS; Smith PD; Barrett JC; Downward J; de Bruin EC
    Nat Commun; 2021 Mar; 12(1):1780. PubMed ID: 33741979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
    Wang H; Pan R; Zhang X; Si X; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):594-602. PubMed ID: 31943845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
    Remon J; Besse B; Aix SP; Callejo A; Al-Rabi K; Bernabe R; Greillier L; Majem M; Reguart N; Monnet I; Cousin S; Garrido P; Robinet G; Garcia Campelo R; Madroszyk A; Mazières J; Curcio H; Wasąg B; Pretzenbacher Y; Fournier B; Dingemans AC; Dziadziuszko R
    Ann Oncol; 2023 May; 34(5):468-476. PubMed ID: 36863484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Takeshita M; Suetsugu T; Kirita K; Ebi N; Hataji O; Miura S; Chibana K; Okamoto I; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    BMC Cancer; 2020 May; 20(1):370. PubMed ID: 32357848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
    Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
    Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Gray JE; Okamoto I; Sriuranpong V; Vansteenkiste J; Imamura F; Lee JS; Pang YK; Cobo M; Kasahara K; Cheng Y; Nogami N; Cho EK; Su WC; Zhang G; Huang X; Li-Sucholeiki X; Lentrichia B; Dearden S; Jenkins S; Saggese M; Rukazenkov Y; Ramalingam SS
    Clin Cancer Res; 2019 Nov; 25(22):6644-6652. PubMed ID: 31439584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncommon
    Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
    Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.
    Li J; Jin M; Diao Y; Li X
    Medicine (Baltimore); 2024 Jul; 103(28):e38789. PubMed ID: 38996163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
    Bennouna J; Girard N; Audigier-Valette C; le Thuaut A; Gervais R; Masson P; Marcq M; Molinier O; Cortot A; Debieuvre D; Cadranel J; Lena H; Moro-Sibilot D; Chouaid C; Mennecier B; Urban T; Sagan C; Perrier L; Barlesi F; Denis MG
    Clin Lung Cancer; 2020 Jan; 21(1):e10-e14. PubMed ID: 31648999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO).
    Pizzutilo EG; Agostara AG; Oresti S; Signorelli D; Stabile S; Lauricella C; Motta V; Amatu A; Ruggieri L; Brambilla M; Occhipinti M; Proto C; Giusti R; Filetti M; Genova C; Barletta G; Gelsomino F; Bennati C; Siringo M; Di Fazio GR; Russano M; Montrone M; Gariazzo E; Roca E; Bordi P; Delmonte A; Scimone A; Belluomini L; Mazzoni F; Carta A; Pelizzari G; Viscardi G; Morgillo F; Gelibter A; Gori S; Berardi R; Cortinovis D; Ardizzoni A; Veronese SM; Sartore-Bianchi A; Giannetta LG; Cerea G; Siena S
    ESMO Open; 2024 Jun; 9(6):103592. PubMed ID: 38878323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).
    Akamatsu H; Teraoka S; Morita S; Katakami N; Tachihara M; Daga H; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2019 Jul; 20(4):e492-e494. PubMed ID: 31085043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Oki M; Tachihara M; Fujimoto D; Hayashi H; Yamaguchi K; Yamamoto S; Iwama E; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Lung Cancer; 2023 Mar; 177():44-50. PubMed ID: 36731290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer.
    Byun JY; Han S; Qdaisat A; Park C
    Expert Opin Drug Saf; 2024 Aug; 23(8):1007-1015. PubMed ID: 38088244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
    Johnson M; Serra Traynor C; Vishwanathan K; Overend P; Hartmaier R; Markovets A; Chmielecki J; Mugundu GM; Barrett JC; Tomkinson H; Ramalingam SS
    Clin Pharmacol Ther; 2024 Feb; 115(2):349-360. PubMed ID: 38010260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.